Manuel Lopez-Figueroa
Director/Board Member presso ORYZON GENOMICS S.A.
Profilo
Manuel López-Figueroa, PhD, is a Managing Director at Bay City Capital and has been with the firm since 2001.
He specializes in evaluating investment opportunities with an emphasis on CNS.
In addition, Dr. López is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience, and genetics from Stanford University, University of Michigan, Cornell University, and the Universities of California at Davis and Irvine.
The consortium aims to discover the neurobiological and genetic determinants of mood disorders and schizophrenia with the goal to develop novel diagnostics and therapeutics.
Dr. López is responsible for planning and directing all aspects of the consortium including strategy, R&D, legal (IP & contracts) and financial, to facilitate the commercialization of discoveries to fund additional research.
Dr. López has over 15 years of experience in the field of neuroscience, has won numerous awards during his academic research career, and has published extensively.
He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark.
Dr. López received a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.
Posizioni attive di Manuel Lopez-Figueroa
Società | Posizione | Inizio |
---|---|---|
ORYZON GENOMICS S.A. | Director/Board Member | 11/05/2020 |
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in San Rafael, California. | Consultant / Advisor | 07/07/2021 |
Imidomics, Inc.
Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Chief Operating Officer | 01/06/2015 |
Cantero Therapeutics, Inc. | Founder | 01/01/2018 |
Zulia Biotech, Inc. | Director/Board Member | - |
Nina Capital SGEIC SA
Nina Capital SGEIC SA Investment ManagersFinance Nina Capital SGEIC SA (Nina Capital) is a venture capital firm founded in 2019 by Marta Gaia Zanchi. It is headquartered in Barcelona, Spain. | Consultant / Advisor | 01/01/2019 |
Formazione di Manuel Lopez-Figueroa
University of Copenhagen | Doctorate Degree |
La Laguna University Of | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
ORYZON GENOMICS S.A. | Health Technology |
Aziende private | 5 |
---|---|
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in San Rafael, California. | Finance |
Imidomics, Inc.
Imidomics, Inc. BiotechnologyHealth Technology Imidomics, Inc. is an American biotechnology company that focuses on discovering and developing new medicines for immune-mediated inflammatory diseases (IMIDs). The company is based in an undisclosed location. Imidomics has access to the IMID-biobank, which includes real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications. The company utilizes a proprietary digital bioinformatics portal called the Imidomics Precision Discovery Platform to generate novel insights into disease mechanisms and identify potential new drug targets. The company was founded in Barcelona in 2015 by Dr. Sara Marsal and Dr. Richard M. Myers. The CEO of the company is Fred Bernard Craves. | Health Technology |
Nina Capital SGEIC SA
Nina Capital SGEIC SA Investment ManagersFinance Nina Capital SGEIC SA (Nina Capital) is a venture capital firm founded in 2019 by Marta Gaia Zanchi. It is headquartered in Barcelona, Spain. | Finance |
Cantero Therapeutics, Inc. | |
Zulia Biotech, Inc. |
- Borsa valori
- Insiders
- Manuel Lopez-Figueroa